Johnson & Johnson (JNJ): Revenue
$94.19B
Year ended 2025-12-28
$99.33B
Trailing 12 months to 2026-09-27
+5.6%
3-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-28 | $94.19B | +6.0% | 2026-02-11, From 2024-12-30 |
| 2024-12-29 | $88.82B | +4.3% | 2026-02-11, From 2024-01-01 |
| 2023-12-31 | $85.16B | +6.5% | 2026-02-11, From 2023-01-02 |
| 2023-01-01, Fiscal 2022 | $79.99B | +1.6% | 2025-02-13, From 2022-01-03 |
| 2022-01-02, Fiscal 2021 | $78.74B | n/c | 2024-02-16, From 2021-01-04 |
| 2021-01-03, Fiscal 2020 | $82.58B | +0.6% | 2023-02-16, From 2019-12-30 |
| 2019-12-29 | $82.06B | +0.6% | 2022-02-17, From 2018-12-31 |
| 2018-12-30 | $81.58B | +6.7% | 2021-02-22, From 2018-01-01 |
| 2017-12-31 | $76.45B | +6.3% | 2020-02-18, From 2017-01-02 |
| 2017-01-01, Fiscal 2016 | $71.89B | n/a | 2019-02-20, From 2016-01-04 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Johnson & Johnson (JNJ) | 2025-12-28 | $94.19B | +6.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $65.18B | +44.7% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $65.01B | +1.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $62.58B | -1.6% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $61.16B | +8.6% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $48.19B | -0.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $44.33B | +5.7% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $17.26B | +4.3% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $14.34B | +1.0% |
Compare JNJ, LLY, MRK, PFE side by side · Screen every company in Pharmaceutical Preparations ↗